Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
Status:
Completed
Trial end date:
2019-02-11
Target enrollment:
Participant gender:
Summary
This trial will evaluate the efficacy of PM060184 in terms of progression-free survival at 12
weeks (PFS3) in advanced or metastatic Colorectal Cancer (CRC) patients with any KRAS
mutation status (wild- type; mutated; or unknown status) progressing after standard
treatments (fluoropyrimidine, irinotecan, and oxaliplatin).
Patients in this trial will receive PM060184 at a dose of 9.3 mg/m2 as a 30-minute
intravenous (i.v.) infusion on Days 1 and 8 q3wk.